Bayer vs. Novartis eye-drug fight intensifies; Pfizer's thyroid med faces sales hurdles; AZ media chief jumps ship;

> Britain's cost-effectiveness gatekeepers backed a new use for Bayer's Eylea vision treatment, in patients with macular edema, stepping up its rivalry with Novartis' ($NVS) Lucentis drug. Report

> Pfizer ($PFE) will resume shipping its thyroid drug Levoxyl after a manufacturing snafu caused a long hiatus; the company now faces a challenge in regaining market share from AbbVie's ($ABBV) Synthroid and generic drugs. Report

> AstraZeneca's ($AZN) global head of media relations, Neil McCrae, has jumped ship to join Royal Mail as its deputy director of communications. Report

> KV Pharmaceutical ($KV.A) created a new maternal health division to focus on marketing products for pregnancy management and tapped Alere Health's Gregg Raybuck to be president of the unit. Report

> Forest Laboratories ($FRX) launched a new support program for chronic obstructive pulmonary disease patients using its treatments for the disease, Tudorza Pressair and Daliresp. Release

> India's Dr Reddy's Laboratories saw its stock surge today after it launched its injectable version of Imitrex, GlaxoSmithKline's ($GSK) migraine drug, in the U.S. Report

And Finally... Algeta shareholders have now tendered more than 97% of their shares to Bayer in the German drugmaker's 2 billion euro takeover. Report

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.